Literature DB >> 8675695

Paradoxical effects of a synthetic metalloproteinase inhibitor that blocks both p55 and p75 TNF receptor shedding and TNF alpha processing in RA synovial membrane cell cultures.

L M Williams1, D L Gibbons, A Gearing, R N Maini, M Feldmann, F M Brennan.   

Abstract

We have previously hypothesized that the pro-inflammatory cytokine TNF alpha has a pivotal role in the pathogenesis of rheumatoid arthritis (RA). It mediates its effects by cross-linking surface p55 TNF receptors (TNF-R), which can be proteolytically cleaved to yield soluble fragments. Upon binding TNF alpha soluble TNF-R (sTNF-R) can inhibit its function. We investigated the enzymatic nature of the proteases involved in TNF-R cleavage, and found that this process is blocked by a synthetic inhibitor of matrix metallo-proteinase activity (MMP), BB-2275. Inhibition of TNF-R cleavage was observed in a number of different cell types, as detected by retention of surface bound TNF receptor and by less sTNF-R released into the cell supernatant. The augmentation of surface TNF-R expression was of biological relevance as TNF alpha-mediated necrosis of human KYM.1D4 rhabdosarcoma cells was enhanced approximately 15-fold in the presence of BB-2275. The addition of BB-2275 to rheumatoid synovial membrane cell cultures totally inhibited MMP activity and also significantly reduced the levels of soluble TNF alpha (P < 0.006), p55 sTNF-R (P < 0.006), and p75 sTNF-R (P < 0.004). Paradoxically, despite the reduction in soluble TNF alpha levels, the production of IL-1 beta, IL-6, and IL-8, cytokines whose production was previously demonstrated to be inhibited by the addition of neutralizing anti-TNF alpha antibody were not down-regulated by BB-2275. These results raise the interesting possibility that a close relationship exits between the enzyme(s) which process membrane-bound TNF alpha, and those involved in surface TNF-R cleavage. Furthermore our observations suggest that hydroxamate inhibitors of MMP activity which block TNF alpha secretion and TNF-R cleavage may not modulate down-stream effects of TNA alpha, and as such suggest that the precise specificity of these compounds will be highly relevant to their clinical efficacy in inflammatory diseases.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8675695      PMCID: PMC507377          DOI: 10.1172/JCI118739

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  48 in total

1.  The activation of human type IV collagenase proenzyme. Sequence identification of the major conversion product following organomercurial activation.

Authors:  W G Stetler-Stevenson; H C Krutzsch; M P Wacher; I M Margulies; L A Liotta
Journal:  J Biol Chem       Date:  1989-01-25       Impact factor: 5.157

2.  Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis.

Authors:  M J Elliott; R N Maini; M Feldmann; A Long-Fox; P Charles; H Bijl; J N Woody
Journal:  Lancet       Date:  1994-10-22       Impact factor: 79.321

3.  Slow release of soluble TNF receptors by monocytes in vitro.

Authors:  J F Leeuwenberg; T M Jeunhomme; W A Buurman
Journal:  J Immunol       Date:  1994-04-15       Impact factor: 5.422

4.  Processing of tumour necrosis factor-alpha precursor by metalloproteinases.

Authors:  A J Gearing; P Beckett; M Christodoulou; M Churchill; J Clements; A H Davidson; A H Drummond; W A Galloway; R Gilbert; J L Gordon
Journal:  Nature       Date:  1994-08-18       Impact factor: 49.962

5.  Purification and biologic characterization of a specific tumor necrosis factor alpha inhibitor.

Authors:  P Seckinger; S Isaaz; J M Dayer
Journal:  J Biol Chem       Date:  1989-07-15       Impact factor: 5.157

6.  The human interferon alpha/beta receptor: characterization and molecular cloning.

Authors:  D Novick; B Cohen; M Rubinstein
Journal:  Cell       Date:  1994-05-06       Impact factor: 41.582

7.  Regulation of tumour necrosis factor-alpha processing by a metalloproteinase inhibitor.

Authors:  G M McGeehan; J D Becherer; R C Bast; C M Boyer; B Champion; K M Connolly; J G Conway; P Furdon; S Karp; S Kidao
Journal:  Nature       Date:  1994-08-18       Impact factor: 49.962

8.  Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing.

Authors:  K M Mohler; P R Sleath; J N Fitzner; D P Cerretti; M Alderson; S S Kerwar; D S Torrance; C Otten-Evans; T Greenstreet; K Weerawarna
Journal:  Nature       Date:  1994-07-21       Impact factor: 49.962

9.  Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro.

Authors:  L A Rubin; C C Kurman; M E Fritz; W E Biddison; B Boutin; R Yarchoan; D L Nelson
Journal:  J Immunol       Date:  1985-11       Impact factor: 5.422

10.  Immunoregulatory role of interleukin 10 in rheumatoid arthritis.

Authors:  P D Katsikis; C Q Chu; F M Brennan; R N Maini; M Feldmann
Journal:  J Exp Med       Date:  1994-05-01       Impact factor: 14.307

View more
  17 in total

Review 1.  A case of tumor betrayal: biphasic effects of TIMP-1 on Burkitt's lymphoma.

Authors:  L Yan; M A Moses
Journal:  Am J Pathol       Date:  2001-04       Impact factor: 4.307

Review 2.  Small therapeutic molecules for the treatment of inflammatory bowel disease.

Authors:  S J H van Deventer
Journal:  Gut       Date:  2002-05       Impact factor: 23.059

3.  A place for TACE.

Authors:  S J H van Deventer
Journal:  Gut       Date:  2002-07       Impact factor: 23.059

4.  Pressure overload-dependent membrane type 1-matrix metalloproteinase induction: relationship to LV remodeling and fibrosis.

Authors:  Michael R Zile; Catalin F Baicu; Robert E Stroud; An Van Laer; Jazmine Arroyo; Rupak Mukherjee; Jeffrey A Jones; Francis G Spinale
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-01-27       Impact factor: 4.733

Review 5.  The future role of anti-tumour necrosis factor (TNF) products in the treatment of rheumatoid arthritis.

Authors:  G Camussi; E Lupia
Journal:  Drugs       Date:  1998-05       Impact factor: 9.546

6.  Biological insights from clinical trials with anti-TNF therapy.

Authors:  M Feldmann; P Charles; P Taylor; R N Maini
Journal:  Springer Semin Immunopathol       Date:  1998

7.  TNFalpha-induced MMP-9 promotes macrophage recruitment into injured peripheral nerve.

Authors:  Veronica I Shubayev; Mila Angert; Jennifer Dolkas; W Marie Campana; Kai Palenscar; Robert R Myers
Journal:  Mol Cell Neurosci       Date:  2005-11-16       Impact factor: 4.314

Review 8.  Tumour necrosis factor and Crohn's disease.

Authors:  S J Van Deventer
Journal:  Gut       Date:  1997-04       Impact factor: 23.059

Review 9.  Membrane protein secretases.

Authors:  N M Hooper; E H Karran; A J Turner
Journal:  Biochem J       Date:  1997-01-15       Impact factor: 3.857

10.  High matrix metalloproteinase production correlates with immune activation and leukocyte migration in leprosy reactional lesions.

Authors:  Rosane M B Teles; Rose B Teles; Thais P Amadeu; Danielle F Moura; Leila Mendonça-Lima; Helen Ferreira; Italo M C F Santos; José A C Nery; Euzenir N Sarno; Elizabeth P Sampaio
Journal:  Infect Immun       Date:  2009-12-14       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.